Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Market Cap & Net Worth: Dermapharm Holding SE (DMPHF)
Dermapharm Holding SE (PINK:DMPHF) has a market capitalization of $2.13 Billion ($2.13 Billion) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #12657 globally and #5394 in its home market, demonstrating a -7.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dermapharm Holding SE's stock price $39.56 by its total outstanding shares 53840000 (53.84 Million).
Dermapharm Holding SE Market Cap History: 2022 to 2025
Dermapharm Holding SE's market capitalization history from 2022 to 2025. Data shows growth from $2.06 Billion to $2.13 Billion (1.52% CAGR).
Dermapharm Holding SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dermapharm Holding SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.95x
Dermapharm Holding SE's market cap is 1.95 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
20.20x
Dermapharm Holding SE's market cap is 20.20 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.06 Billion | $1.02 Billion | $134.24 Million | 2.01x | 15.31x |
| 2023 | $2.11 Billion | $1.15 Billion | $62.37 Million | 1.83x | 33.79x |
| 2024 | $2.30 Billion | $1.18 Billion | $113.79 Million | 1.95x | 20.20x |
Competitor Companies of DMPHF by Market Capitalization
Companies near Dermapharm Holding SE in the global market cap rankings as of March 19, 2026.
Key companies related to Dermapharm Holding SE by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dermapharm Holding SE Historical Marketcap From 2022 to 2025
Between 2022 and today, Dermapharm Holding SE's market cap moved from $2.06 Billion to $ 2.13 Billion, with a yearly change of 1.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.13 Billion | -7.32% |
| 2024 | $2.30 Billion | +9.04% |
| 2023 | $2.11 Billion | +2.52% |
| 2022 | $2.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Dermapharm Holding SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.13 Billion USD |
| MoneyControl | $2.13 Billion USD |
| MarketWatch | $2.13 Billion USD |
| marketcap.company | $2.13 Billion USD |
| Reuters | $2.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.